Objective: To determine the multidrug-resistant transporter (MDR) activity in oocytes and their potential role in oocyte susceptibility to chemotherapy. Design: Experimental laboratory study. Setting: University and academic center for reproductive medicine. Subject(s): Women with eggs retrieved for intracytoplasmic sperm injection cycles and adult female FVBN and B6C3F1 mouse strains.
A n estimated 790,740 women in the United States were diagnosed in 2012 with some form of cancer. Approximately 8%, or 60,000, of these women were under the age of 40 years (National Cancer Institute Surveillance, Epidemiology, and End Results Database, [2005] [2006] [2007] [2008] [2009] ). Current treatment regimens use aggressive chemotherapy aimed at cure. Unfortunately, the alkylating agents used, such as busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, and thiotepa, can often induce premature ovarian failure, rendering the patient infertile and hormonally compromised (1) . Women have the option to preserve their fertility through IVF followed by embryo cryopreservation, ovarian tissue cryopreservation, metaphase II (MII) oocyte cryopreservation, and administration of GnRH agonists (2) . However, women are less likely to be offered fertility preservation options compared with men (3) , and this is true also in the pediatric cancer population (4) . The opportunity to preserve fertility may also be limited by financial constraints and lack of insurance coverage (5) . Therefore, the gonadotoxicity of the chemotherapy occurs before any discussion of the current standards of care can be presented to the patient. This has resulted in chemotherapy-induced toxicity quickly becoming a leading cause of ovarian failure, which predisposes the patient to early onset of menopause-associated risks such as accelerated bone loss, increased cardiovascular risk, and sexual dysfunction in addition to infertility severely affecting their quality of life after surviving cancer (6) .
Current thinking is that chemotherapeutic agents deplete the pool of primordial follicles and immature oocytes in a drug-and dose-dependent manner. However, work in mice showed that whole ovaries exposed to doxorubicin, an anthracycline, underwent apoptosis through acute injury of the vasculature and that apoptosis occurred in all follicular stages but only significantly in those at the secondary stage (7). Soleimani et al. (8) reported in 2012 that doxorubicintreated ovaries showed double-strand DNA breakage-mediated apoptosis in primordial follicles, oocytes, and granulosa cells in a dose-dependent manner. Their data also showed that stromal and vascular damage was implicated in ovarian failure after treatment with doxorubicin. In a recent review by Morgan et al. (9) , 17 studies were selected to ascertain whether the mammalian oocyte or the granulosa cells were the main target of various chemotherapeutics, including cisplatin, doxorubicin, and cyclophosphamide. No conclusion could be made from those studies as to whether germ or somatic cell demise is truly responsible for the observed ovarian damage. A very different perspective has emerged in a study by Kalich-Philosoph et al. (10) , which proposes a new mechanism for ovarian insufficiency that accelerated primordial cell activation may result in ''burn-out'' and follicle depletion. A definite understanding of the mechanism of ovarian insufficiency has yet to be universally accepted.
It is known that protection from chemotherapy drugs is often observed from multidrug-resistant (MDR) transporters, although our understanding of these gene products in the ovarian context is poor. Plasma membranes control the flow of molecules between cells and their environment, and the ATP-binding cassette (ABC) transporters, also dubbed MDR transporters, are transmembrane proteins found in cells that provide protection by exporting toxins and xenobiotics (11) (12) (13) (14) . MDR transporters also function to protect cells from toxic substances, including chemotherapeutics, stimulating a second-tier approach to block their activity to increase effectiveness of the therapy. P-Glycoprotein (P-gp), or MDR-1, is the archetypal transporter with the most clinical importance, and overexpression of P-gp is believed to be responsible for drug resistance in many tumors.
MDR transporters are expressed in a variety of reproductive cell types, including oocytes. Murine oocytes and early embryos express P-gp, which is thought to protect them against toxicants (14) . However, the relative activity levels and role of MDR transporters in the oocyte and somatic cells of the ovary has yet to be identified. Studies in oocytes of sea stars (starfish) and pigs have found that MDR transporter activity increase as they mature from germinal vesicle (GV) stage to mature eggs in meiosis II (MII) (15) (16) (17) . The phenomenon of P-gp up-regulation has also been observed in porcine oocytes and granulosa cells matured by in vitro maturation (17) . Further, ABC efflux transporters have been implicated in fertility, because mutations of ABCC7 (CFTR) have been found to be associated with abnormalities in ovulation and/or oocyte maturation in mice (18) .
Herein, we demonstrate the expression of MDR transporters in mouse and human oocytes at the GV, meiosis I (MI), and MII stages by observing directly the efflux of fluorescent dye substrates of MDR transporters. We also show that Novartis PSC 833, a cyclosporine analogue, effectively blocks reporter efflux in the mouse and human oocyte in vitro, further clarifying the MDR transporter activity. We further demonstrate that the inhibition of MDR transporters leads to increased susceptibility of the oocyte to the toxicity of chemotherapy, particularly cyclophosphamide, a drug that alkylates and cross-links DNA. These data could help to elucidate at which stage oocytes are most sensitive to chemotherapy and what role MDR transporters may play in the protection of the oocyte in addition to its supportive granulosa cells.
MATERIAL AND METHODS

Oocyte Sources
Ovaries were harvested from murine B6C3F1 strains from Embryotech by mechanically disrupting follicles with a tuberculin 25-gauge needle. A Drummond pipette was then used to denude oocytes, which were then separated and pooled for experimentation. MII oocytes were recovered from the oviducts of superovulated mice given 5 U PMSG and 75 IU hCG. Deidentified human oocytes deemed to be unsuitable for intracytoplasmic sperm injection because of GV or MI stage were collected from the IVF Laboratory at the Center for Reproduction and Infertility at Women and Infants Hospital after obtaining Institutional Review Board approval for residual tissue studies. These oocytes were either treated immediately or placed into in vitro maturation media supplemented with 7.5 IU FSH and 7.5 IU LH. When necessary, oocytes were denuded chemically with 80 U hyaluronidase and/or mechanically with micropipettes.
Immunoblot
For immunoblots with C19 (sc-1517; Santa Cruz Biotechnology), samples of 50 pooled oocytes of each stage were placed in 20 mL of 2Â sodium dodecyl sulfate loading buffer and stored at À20 C. Protein samples were prepared by adding 1 mmol/L dithiothreitol to the sample, and the solutions were then boiled for 2 minutes taking care to avoid evaporation. Samples were loaded onto a 4%-20% gradient Tris-glycine polyacrylamide gel (Invitrogen) and run at 125 V for 106 minutes at room temperature. Proteins were transferred to nitrocellulose for 70 minutes at 30 V in a cooled chamber. Blots were blocked for 2-3 hours in 4% nonfat milk in Tris-buffered saline solution (TBS; 10 mmol/L Tris, 150 mmol/L NaCl, pH 7.4) and stored overnight in TBS with 1% Tween. P-gp was labeled by incubating blots overnight at 4 C with goat polyclonal antibody C19 at 1:500, followed by horseradish peroxidase (HRP)-conjugated donkey antigoat antibody (diluted 1:3,000) for 1 hour. HRP-labeled P-gp was visualized by incubation in a chemiluminescence solution (1.25 mmol/L luminol, 68 mmol/L coumeric acid, 0.0093% hydrogen peroxide, and 0.1 mol/L Tris, pH 8.6) for 1 minute, exposed to film, and developed. MII eggs from the sea star Patiria miniata, which were previously shown to express MDR-1, were used as positive control (15) .
Quantitative PCR
Primers to the unique regions of the MDR-1 transcript (forward 5
0 -cacagcttgtccagccaat-3 0 and reverse 5 0 -acttctcgaagatgggcaa-3 0 ) as well as to the transcripts for b-actin and 18S rRNA in mice were designed. Oocytes were pooled in RNA Lysis Buffer and stored at À80 C until pools of 25-30 oocytes of each stage could be assembled. Using the RNA Easy microkit (Qiagen), RNA was extracted and reverse transcription used to make cDNA with the use of the Taqman Kit (Applied Biosystems). Reverse-transcription polymerase chain reaction (PCR) was then performed.
Fluorescence Efflux Activity
All dye and chemotherapy experiments were recorded with the use of confocal microscopy (Zeiss 510 meta) equipped with a 37 C stage and Trigas chamber (composed of 90% N, 5% CO 2 , and 5% O 2 , mimicking IVF incubator conditions). Oocytes from the GV to the MII stage were incubated with calcein AM dye for 1 hour and washed. Under confocal microscopy, oocyte fluorescence intensity was monitored longitudinally and recorded with an excitation of 495 nm and 518 nm emission for calcein AM. Images were then quantified over time with the use of Metamorph imaging software (Universal Imaging Corp.).
Oocyte Chemotherapy Susceptibility
After performing a dose curve, mouse oocytes were incubated with 25 mmol/L of cyclophosphamide with or without $25 mmol/L PSC 833. In addition, human oocytes were incubated with 80 mmol/L of cyclosphosphamide for 12 hours with or without 10 mmol/L PSC 833. To determine cell death, 0.04% trypan blue was used as a dye exclusion viability test as well as the Live/Dead Viability/Cytotoxicity Assay (Invitrogen) to quantify cell death in these oocytes. Human oocyte fluorescence results were quantified with the use of Metamorph.
Immunofluorescence
Isolated mouse oocytes were fixed in 4% paraformaldehyde in phosphate-buffered saline solution (PBS; NaCl 137mM, KCl 2.7mM, Na2HPO4 10mM, KH2PO4 1.8mM, CaCl2.2H2O 1mM, MgCl2.6H2O 0.5mM) and stored at 4 C until ready for use. The oocytes were then washed in immunofluorescence (IF) buffer (PBS and 0.4% Triton) three times for 10 minutes each. After establishing a titration curve with the primary antibodies, the oocytes were incubated with MDR-1 (Santa Cruz Biotechnology sc-1517; diluted 1:250) at 4 C overnight followed by three 10-minute washes in IF buffer. The oocytes were then incubated with secondary antibodies (Alexa 488 donkey antigoat 1:5,000), also diluted in PBS and 0.4% Triton, for 1 hour at room temperature, followed by three 10-minute washes. A secondary control (no primary) of oocytes was also prepared and processed simultaneously. Finally, the oocytes were mounted between slide and coverslip and visualized with a 510 LSM laser scanning confocal microscope (Zeiss). Optical sections of 1 mm were obtained, and the imaging parameters were set with the use of the grayscale function in the Zen software (Zeiss) so that all the images were recorded equally and under the point of saturation. The images were then exported as TIFF files and analyzed with the use of Metamorph.
Data Analysis
Fluorescence intensity was measured for individual oocytes with the use of Metamorph software. All absolute measurements were averaged (AE1 SD). Data are reported as average fluorescence intensity with differences between treatments analyzed with the use of two-sample paired t tests of means (with a significance cutoff of P< .05). Chemotherapyinduced cell death was quantified with the use of trypan blue dye exclusion test and the Live/Dead Viability/Cytotoxicity Assay according to manufacturers' instructions.
RESULTS
Diversity of MDR Transporters in the Oocyte
We used recently acquired transcriptomic results to computationally probe the repertoire of mRNAs present in mouse and human oocytes (19, 20) . We found from single-cell analysis of largely MI oocytes $25 different MDR transporter genes present in both mouse and humans, representing a large diversity of ABC subfamily members (Supplemental Figs. 1  and 2 ; Supplemental Figs. 1-7 are available online at www.fertstert.org). Although each transporter has not been fully characterized, and their precise substrates for efflux have not been defined, we think the results presented here likely represent a much larger set of transporters present in the cell. Furthermore, it is of interest that in the Taf4b knockout mouse, a model for primary ovarian insufficiency, that transcripts of some ABC transporters are significantly higher in wild type (WT) compared with the knockout (e.g., ABCa1: WT 5.3, KO 1.48) whereas several transporter transcripts are markedly elevated in the KO compared with WT (e.g., ABCf3: WT 0, KO 40.29; ABCb1b: WT 1.31, KO 15.48; ABCb4: WT 17.91, KO 49.87 (Supplemental Fig. 1 ).
Dynamic Expression of MDR Protein and mRNA during Oocyte Maturation
When transcript levels of MDR-1 were tested by quantitative PCR, MII oocytes showed an increase compared with GV (Fig. 1A) . Immunoblots of oocytes of various stages documented a single band of 65 kDa in GV, MI, and MII stages. When normalized to number of oocytes, this result revealed more signal intensity in the GV pool of oocytes compared with MI and MII pools (Fig. 1B) . This result is supported by immunolocalization in oocytes: Using the same antibody between blots and in situ immunolabeling, the fluorescence signal in GV oocytes is markedly more intense compared with M2 oocytes (Fig. 1C; Supplemental Figs. 3 and 4) . These results may mean that the mRNA increase for MDR-1 seen in MII oocytes is not translated but perhaps stored for use later, after fertilization and during embryogenesis. Recently, many mRNAs in the oocyte have been shown to be under translational control by a variety of means (21) , and the results obtained here suggest that at least MDR-1 is also regulated posttranscriptionally. These results may offer new approaches to therapeutic promise in the future.
Oocytes Exhibit Significant and Dynamic MDR Efflux Activity during Maturation
Calcein AM is a valuable reporter for MDR transporter activity in a cell. It enters the cell by diffusion as a result of its AM group, which is then cleaved off by endogenous esterase activity, trapping the fluorescent marker in the cell. Effluxing of this reporter is selective for MDR-1/P-gp in the oocyte's plasma membrane and is the criterion standard for studying transporter function. Efflux activity with calcein AM was detected in all stages of oocytes, and the relative activity decreased in M2 oocytes compared to the earlier stages of germinal vesicles ( Fig. 2; Supplemental Fig. 5 ). Polar bodies of the MII oocytes also appeared to efflux the dyes although somewhat less efficiently than its sibling oocyte. The rate of calcein efflux for GV stages was higher than that seen in MII oocytes, with P< .05. Interestingly, in the GV stage dye does not enter the GV itself but instead remains in the cytoplasm. That removal of the calcein reporter from the cell is mediated by MDR transporter is supported by use of the P-gp inhibitor PSC 833. This inhibitor is specific for P-gp MDR transporters, and the effect on the oocyte is a dramatic loss ($10-fold) of efflux capability in the oocytes at GV and MI stages. MII-stage oocytes are much less efficient at effluxing in general, so the inhibitory effect of PSC 833 is significantly less.
MDR-1 Functions in Chemotherapy Susceptibility
Oocytes at all maturational stages showed significantly decreased MDR-1 activity when treated with the specific MDR-1 inhibitor PSC 833. This result supports the contention that calcein efflux is indeed occurring through the MDR-1 channel. Both mouse and human oocytes exposed to cyclophosphamide and PSC 833 showed cell death with the Live/Dead Viability/Cytotoxicity assays compared with oocytes treated with media alone, PSC 833 alone, or cyclophosphamide alone (Figs. 3 and 4) . Cell death was also observed by trypan blue on human oocytes treated with cyclophosphamide and PSC 833 (Supplemental Fig. 6 ). Here, to better understand the role of MDRs in oocytes, we purposely chose concentrations of cyclophosphamide that did not induce apoptosis on its own. Although the internal concentrations of this drug in the oocyte are unknown, the concentrations used herein are likely much The fluorescence resulting from the calcein in the whole oocytes was quantified using metamorph. 12 GV, 7 MI, and 8 MII were used for the quantification in the control; 9 GV, 4 MI, and 7 MII were analyzed after the PSC833 treatment. Significance was assessed between control (without PSC) and PSC833 treated oocytes (with PSC) for each developmental stage using Student t test, P<.005. Significant differences (*) were obtained for each stage. 
FIGURE 3
Multidrug-resistant (MDR) transporter activity is essential for the survival of mouse oocytes exposed to a chemotherapeutic agent. (A) Cell death was measured with the use of the Live/Dead assay. GV, MI, and MII mouse oocytes were incubated for 12 hours with 25 mmol/L cyclophosphamide only (panels b, k, t; e, n, w; and h, q, z) or in the presence of 25 mmol/L cyclophosphamide and 25 mmol/L PSC 833 (panels c, l, u; f, o, x; and i, r, a). Untreated oocytes were used as control (panels a, j, s; d, m, v; and g, p, y). The Live/Dead assay was performed by simultaneously monitoring the fluorescence after addition of calcein AM (panels j-r) and ethidium homodimer 1 (panels s-a). Calcein AM (green) is retained in live cells, whereas ethidium homodimer 1 (red) enters dead cells. The corresponding differential interference contrast images are shown in panels a-i. Scale bar ¼ 100 mm. (B) The fluorescence was quantified with the use of Metamorph. For each oocyte, only a small area was considered for the fluorescence measurement to avoid the surrounding granulosa cells. Cell viability is represented on the graph with the use of a relative unit: ratio of green/ red fluorescence measured in each oocyte. The number of oocytes used for each condition is indicated in parentheses. Significance was assessed between oocytes treated with cyclophosphamide without or with PSC 833 for each developmental stage with the use of Student t test (P<.005). *Significant differences were obtained for each stage.
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higher than oocytes experience, forming a test of MDR activity of high stringency.
DISCUSSION
The cost of chemotherapeutic treatment in reproductive-age women is premature loss of primordial follicles or perhaps accelerated activation leading to early onset of menopause. Chemotherapy-induced toxicity is rapidly becoming a leading cause of ovarian sufficiency, which predisposes the patient to early onset of menopause-associated risks such as accelerated bone loss, increased cardiovascular risk, and sexual dysfunction in addition to infertility (6) . Protection from xenobiotics in cells often results from MDR transporters; P-gp is the best understood MDR transporter in mammalian cells. The exact role of the MDR transporter in oocytes has yet to be determined, although investigators (15) have shown in oocytes of the sea star that their function is not in maturation of the oocyte. Yet they did find that these transporters are mobilized as the oocyte matures. MDR transporters appear to be highly conserved, perhaps reflecting their crucial roles in effluxing of metabolites, xenobiotics, and perhaps even signaling molecules (22, 23) . In the case of sea stars, which broadcast-spawn their oocytes into the environment, it is plausible that the transporters serve as protection to their germ line. Perhaps mammalian oocytes have retained the capacity to accomplish this, given that the oocytes must endure the often lengthy reproductive life of the animal which may include exposure to toxicants such as metabolites, chemicals, and chemotherapeutics. Our transcriptomic results suggest that the MDR transporter profile of cells can be dramatically changed either directly or indirectly by transcriptional activity of the cell (19) . This may reflect a potential target for modulating MDR transporter activity, and differences of such activities naturally in cells may explain why some oocytes have better xenobiotic resistance than others. At least for the present study, it suggests a much broader level of MDR transporter presence than previously considered.
We have shown herein that mouse and human oocytes have active effluxers, and that MDR transporter-dependent dye is removed from the cell in GV-stage oocytes more effectively than in MII-stage oocytes. This finding of relative activity is different than seen in the sea star oocyte as well as the pig oocyte (15, 16, 24) , which has more efflux activity as it matures. Perhaps in starfish, which spawn their mature eggs from a continuous stem cell supply, there may be an advantage to up-regulating MDR transporter activity at the MII stage which will be exposed to environmental conditions in the benthos, compared with mammals, who have a finite reserve of long-lived oocytes with ootoxic exposures occurring over prolonged periods. This ''limited supply,'' although being challenged by recent work (24) , may be why immature oocytes are preferentially protected, because they are present in the animal for the duration of its reproductive years. Although it is clear that GV oocytes do not have significantly more transporters, it appears that their efflux activity is more efficient compared with later stages. This is evidenced by increases in calcein AM fluorescence retention in more mature MI and MII oocytes. We think that most, if not all, of the reporter efflux is via MDR transporters, because use of only the MDR-1 transport inhibitor PSC 833 retains dye significantly. Calcein AM dye in particular works by first diffusing into the cell as a result of the AM-conjugated group. However, because the AM conjugation is labile to endogenous esterase activity, the AM-cleaved product results in calcein now trapped in the cell. Its only known exit mechanism is effluxing through the MDR transporters, and this conclusion is supported in both human and mouse oocytes by use of the MDR-1 inhibitor PSC 833, with which the dye no longer leaves the cell and instead remains trapped within the cytoplasm.
When oocytes are exposed to cyclophosphamide levels as used herein, they survive. However, if the MDR-1 is inhibited and the oocytes are exposed to the chemodrugs, the oocytes are no longer viable. This is supportive of the work by Kalich-Philosoph et al. (10) , who also showed that cyclophosphamide does not destroy primordial follicle oocytes directly through apoptosis. Although the level of each drug that actually reaches the oocyte in vivo is unknown, we used a range of concentrations to test the protection provided by the MDR repertoire in the cell. The results suggest that MDR transport may be vital to oocyte protection especially in crucial transition of an oocyte during maturation. Further study is needed to comprehend the basic physiologic process of MDR in primordial follicles and maturing oocytes so that this transporter can be understood to maximally protect primordial follicles and growing oocytes from toxicity. Additionally, MDR activity may be crucial for the survival of the entire population of follicles, because it is also detected in the granulosa cells (Supplemental Fig. 7 ), which merits further investigation. MDR transporter function in oocytes and whole follicles could serve as a model for assessing environmental reproductive toxicants as well as other chemotherapeutics.
